ES2248514T3 - Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procedimientos de preparacion y su utilizacion terapeutica. - Google Patents

Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procedimientos de preparacion y su utilizacion terapeutica.

Info

Publication number
ES2248514T3
ES2248514T3 ES02700318T ES02700318T ES2248514T3 ES 2248514 T3 ES2248514 T3 ES 2248514T3 ES 02700318 T ES02700318 T ES 02700318T ES 02700318 T ES02700318 T ES 02700318T ES 2248514 T3 ES2248514 T3 ES 2248514T3
Authority
ES
Spain
Prior art keywords
somatostatin
preparation procedures
receptors
derivatives
dihidrotiazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02700318T
Other languages
English (en)
Inventor
Christophe Moinet
Carole Sackur
Christophe Thurieau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Application granted granted Critical
Publication of ES2248514T3 publication Critical patent/ES2248514T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal (AREA)
  • Thin Film Transistor (AREA)

Abstract

La presente solicitud tiene como objetivo nuevos derivados de 2-arilimino-2, 3-dihidrotiazoles y sus procedimientos de preparación. Estos productos tienen una buena afinidad por determinados subtipos de receptores de la somatostatina y por lo tanto, presentan interesantes propiedades farmacológicas. La invención se refiere igualmente a estos mismos productos como medicamentos destinados a tratar estados patológicos o enfermedades en las que está(n) implicado(s) uno (o varios) de estos receptores de somatostatina. La somatostatina (SST) es un tetradecapéptido cíclico que se aisló por primera vez del hipotálamo como sustancia inhibidora de la hormona del crecimiento. Interviene también como neurotransmisor en el cerebro. La clonación molecular ha permitido mostrar que la bioactividad de la somatostatina depende directamente de una familia de cinco receptores ligados a la membrana.
ES02700318T 2001-01-12 2002-01-11 Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procedimientos de preparacion y su utilizacion terapeutica. Expired - Lifetime ES2248514T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0100396 2001-01-12
FR0100396A FR2819508B1 (fr) 2001-01-12 2001-01-12 Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques

Publications (1)

Publication Number Publication Date
ES2248514T3 true ES2248514T3 (es) 2006-03-16

Family

ID=8858747

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02700318T Expired - Lifetime ES2248514T3 (es) 2001-01-12 2002-01-11 Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procedimientos de preparacion y su utilizacion terapeutica.

Country Status (26)

Country Link
US (1) US7220765B2 (es)
EP (1) EP1353912B1 (es)
JP (1) JP4452443B2 (es)
KR (1) KR100874298B1 (es)
CN (1) CN100534988C (es)
AR (1) AR035730A1 (es)
AT (1) ATE302765T1 (es)
AU (1) AU2002233407B2 (es)
BR (1) BR0206407A (es)
CA (1) CA2434203C (es)
CZ (1) CZ20031917A3 (es)
DE (1) DE60205717T2 (es)
DK (1) DK1353912T3 (es)
ES (1) ES2248514T3 (es)
FR (1) FR2819508B1 (es)
HU (1) HUP0500958A3 (es)
IL (2) IL156647A0 (es)
IS (1) IS2331B (es)
MX (1) MXPA03006249A (es)
MY (1) MY142762A (es)
NO (1) NO325484B1 (es)
NZ (1) NZ526692A (es)
PL (1) PL367627A1 (es)
RU (1) RU2283838C2 (es)
WO (1) WO2002055510A1 (es)
ZA (1) ZA200305100B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4896387B2 (ja) * 2003-09-30 2012-03-14 武田薬品工業株式会社 チアゾリン誘導体およびその用途
EA200800817A1 (ru) 2005-09-13 2008-08-29 Байер Кропсайенс Аг Пестицидные производные бифениламидина
KR100863239B1 (ko) 2007-05-23 2008-10-15 한국과학기술연구원 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
US20110105736A1 (en) * 2008-06-23 2011-05-05 Tosoh Corporation Separating agent for protein purification and protein purification method
KR101049935B1 (ko) 2008-12-03 2011-07-15 한국과학기술연구원 신규한 티아졸린계 화합물 및 이를 포함하는 ｔ-형 칼슘 채널 저해제
ES2351569B8 (es) * 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
CN104803997A (zh) * 2010-08-09 2015-07-29 株式会社创药分子设计 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂
RU2521390C1 (ru) * 2013-03-14 2014-06-27 Общество с ограниченной ответственностью "Тиацен" Производное роданина и средство для профилактики опухолевых заболеваний
WO2018030840A1 (ko) * 2016-08-12 2018-02-15 가톨릭대학교 산학협력단 연조직 경화용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1347371A (fr) * 1962-01-19 1963-12-27 Ciba Geigy Agents de lutte contre les organismes nuisibles, renfermant des thiazolines, à usages agricoles et industriels
DE2926771A1 (de) * 1979-07-03 1981-01-15 Hoechst Ag Thiazolidinderivate und verfahren zu ihrer herstellung
DE3049460A1 (de) * 1980-12-30 1982-07-29 Hoechst Ag, 6000 Frankfurt "thiazolinderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2796643B1 (fr) * 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

Also Published As

Publication number Publication date
PL367627A1 (en) 2005-03-07
NO20033120D0 (no) 2003-07-08
JP4452443B2 (ja) 2010-04-21
KR100874298B1 (ko) 2008-12-18
NO325484B1 (no) 2008-05-13
FR2819508B1 (fr) 2005-01-21
EP1353912B1 (fr) 2005-08-24
NO20033120L (no) 2003-09-11
CA2434203C (fr) 2010-12-07
HUP0500958A3 (en) 2009-12-28
US7220765B2 (en) 2007-05-22
HUP0500958A2 (en) 2006-01-30
CA2434203A1 (fr) 2002-07-18
EP1353912A1 (fr) 2003-10-22
MY142762A (en) 2010-12-31
RU2283838C2 (ru) 2006-09-20
IL156647A (en) 2009-07-20
WO2002055510A1 (fr) 2002-07-18
BR0206407A (pt) 2004-01-06
JP2004530643A (ja) 2004-10-07
CN1871224A (zh) 2006-11-29
IL156647A0 (en) 2004-01-04
FR2819508A1 (fr) 2002-07-19
ATE302765T1 (de) 2005-09-15
ZA200305100B (en) 2004-08-27
NZ526692A (en) 2006-04-28
KR20040038905A (ko) 2004-05-08
US20070043095A1 (en) 2007-02-22
AR035730A1 (es) 2004-07-07
MXPA03006249A (es) 2003-09-22
DE60205717T2 (de) 2006-06-22
DE60205717D1 (de) 2005-09-29
IS2331B (is) 2008-02-15
CZ20031917A3 (cs) 2004-05-12
CN100534988C (zh) 2009-09-02
RU2003124749A (ru) 2005-01-10
AU2002233407B2 (en) 2006-11-23
DK1353912T3 (da) 2006-01-09
IS6870A (is) 2003-07-09

Similar Documents

Publication Publication Date Title
ES2248514T3 (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procedimientos de preparacion y su utilizacion terapeutica.
IL199914B (en) Use of protein kinase n beta to produce a diagnostic agent
DK0861261T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
BRPI0510501A (pt) antagonistas do receptor 3 de histamina
GT200400076A (es) Ligandos de receptores de cannabinoides y sus usos
CO6251322A2 (es) Polipeptidos dominios variables de anticuerpos y antagonistas
AR071732A1 (es) Metodos para tratar la enfermedad de alzheimer, reducir la disminucion del volumen cerebral y monitorear una poblacion de pacientes que experimentan tratamiento o profilaxis para una enfermedad, uso de una medida de numero de copia apoe4, forma humanizada de un anticuerpo y acido nucleico aislado.
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
BRPI0716811B8 (pt) anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástases
BR0310092A (pt) Combinação de compostos orgânicos
DE69638022D1 (de) Aus wirbeltieren und darauf basierende verfahren
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
ATE554108T1 (de) Verfahren bezüglich ldcam und crtam
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
NO20053773L (no) Parentale peptidformuleringer for behandling av systemisk lupus erytematosus
HRP20220426T1 (hr) Proteini koji vezuju antigen koji aktiviraju receptor leptina
BR0314212C1 (pt) projeto de análogos a quimiocina de proteìna-10 (ip-10 ou cxcl10) induzìveis por interferon para o tratamento de doenças humanas
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
BRPI0411661A (pt) derivados de n-fenil-piperazina e métodos de profilaxia ou tratamento de doenças associadas com o receptor 5ht 2c
BRPI0506494A (pt) compostos de silinano como inibidores de cisteìna protease
BRPI0407055A (pt) Derivados de isotiazol
NO20015247L (no) Glysinspaltingssysteminhibitorer som potensielle antipsykotika
UY28347A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación